Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg

Curr Rheumatol Rev. 2020;16(4):280-284. doi: 10.2174/1573397115666191106120622.

Abstract

Background: Small fiber neuropathy and fibromyalgia are two conditions that share overlapping features. Although various treatments are available for use in fibromyalgia, the response often remains unsatisfactory. Prior studies have shown that in small fiber neuropathy of autoimmune etiology, intravenous immunoglobulin (IVIg) holds promise as an effective treatment.

Methods: Herein we report the use of IVIg in 7 patients who have both fibromyalgia and small fiber neuropathy. Skin punch biopsy evaluating the nerve fiber density was performed prior to diagnosis and after 6 months of IVIg therapy in each individual. Patients' symptoms were obtained via a fibromyalgia questionnaire pre- and post-treatment.

Results and conclusion: At the end of 6 months therapy, overall patients reported fewer fibromyalgia symptoms and skin biopsy demonstrated improvements as well. This retrospective pilot study suggests IVIg is a viable potential therapy in a subset of fibromyalgia patients who have small fiber neuropathy.

Keywords: IVIG; Small fiber neuropathy; autoimmune; etiology; fibromyalgia; small fiber neuropathy.

MeSH terms

  • Fibromyalgia / complications
  • Fibromyalgia / diagnosis*
  • Fibromyalgia / drug therapy*
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Nerve Fibers / drug effects
  • Nerve Fibers / pathology*
  • Pilot Projects
  • Retrospective Studies
  • Small Fiber Neuropathy / complications
  • Small Fiber Neuropathy / diagnosis*
  • Small Fiber Neuropathy / drug therapy*

Substances

  • Immunoglobulins, Intravenous